Not provided
Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| MK0777-019 | |||
| 2007_630 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The study will look at the effectiveness of MK0777 in patients with Generalized Anxiety Disorder.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| 1 | Experimental | Drug |
|
| 2 | Placebo Comparator | Placebo |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| MK0777 | Drug | Days 1-3 3mg MK0777, Days 4-7 6 mg MK0777, Days 8-28 3, 6 or 9 mg MK0777 |
| |
| Measure | Description | Time Frame |
|---|---|---|
| Measure the reduction of anxiety | after 4 weeks and at end of study |
| Measure | Description | Time Frame |
|---|---|---|
| Safety and efficacy | throughout study and at end of study |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Medical Monitor | Merck Sharp & Dohme LLC | Study Director |
Not provided
Not provided
| ID | Term |
|---|---|
| D000098647 | Generalized Anxiety Disorder |
| ID | Term |
|---|---|
| D001008 | Anxiety Disorders |
| D001523 | Mental Disorders |
Not provided
Not provided
| ID | Term |
|---|---|
| C507018 | 7-(1,1-dimethylethyl)-6-(2-ethyl-2H-1,2,4-triazol-3-ylmethoxy)-3-(2-fluorophenyl)-1,2,4-triazolo(4,3-b)pyridazine |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Placebo (unspecified) |
| Drug |
matching placebo |
|